Build status - In Progress

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Recruiting
18 years - 99 years
All
Phase 3
175 participants needed
1 Location

Brief description of study

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Myasthenia Gravis
  • Age: 18 years - 99 years
  • Gender: All

Male and Female, Age 18 or older, Diagnosis of Myasthenia Gravis

Updated on 04 Aug 2024. Study ID: 834121

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center